PTX3 inhibits angiogenesis Selective recognition of fibroblast growth factor-2 by the long pentraxin

The long pentraxin PTX3 is a soluble pattern recognition receptor produced by monocytes and endothelial cells that plays a nonredundant role in inflammation. Several pathologic conditions are characterized by local production of both PTX3 and the angiogenic fibroblast growth factor-2 (FGF2). Here, solid-phase binding assays demonstrated that PTX3 binds with high affinity to FGF2 but not to a panel of cytokines and growth factors, including FGF1, FGF4, and FGF8. Accordingly, PTX3 prevented (125)I-FGF2 binding to endothelial cell receptors, leading to specific inhibition of FGF2-induced proliferation. PTX3 hampered also the motogenic activity exerted by endogenous FGF2 on a wounded endothelial cell monolayer. Moreover, PTX3 cDNA transduction in FGF2-transformed endothelial cells inhibited their autocrine FGF2-dependent proliferation and morphogenesis in vitro and their capacity to generate vascular lesions when injected in nude mice. Finally, PTX3 suppressed neovascularization triggered by FGF2 in the chick embryo chorioallantoic membrane with no effect on physiologic angiogenesis. In contrast, the short pentraxin C-reactive protein was a poor FGF2 ligand/antagonist. These results establish the selective binding of a member of the pentraxin superfamily to a growth factor. PTX3/FGF2 interaction may modulate angiogenesis in various physiopathologic conditions driven by inflammation, innate immunity, and/or neoplastic transformation.

[1]  M. Rocchi,et al.  Interleukin-1-inducible genes in endothelial cells. Cloning of a new gene related to C-reactive protein and serum amyloid P component. , 1992, The Journal of biological chemistry.

[2]  J. Vilček,et al.  TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. , 1993, Journal of immunology.

[3]  A. Mantovani,et al.  Long Pentraxin PTX3 Upregulates Tissue Factor Expression in Human Endothelial Cells: A Novel Link Between Vascular Inflammation and Clotting Activation , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[4]  H. Land,et al.  Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. , 1990, Nucleic acids research.

[5]  G. Taraboletti,et al.  The 140-kilodalton antiangiogenic fragment of thrombospondin-1 binds to basic fibroblast growth factor. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[6]  M. Nugent,et al.  Endothelial proteoglycans inhibit bFGF binding and mitogenesis , 1997, Journal of cellular physiology.

[7]  A. Mantovani,et al.  PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. , 2001, Arthritis and rheumatism.

[8]  M. Reidy,et al.  Factors controlling the development of arterial lesions after injury. , 1992, Circulation.

[9]  M. Presta,et al.  Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration , 1986, Molecular and cellular biology.

[10]  C. Blobel,et al.  Apexin, an acrosomal pentaxin. , 1994, The Journal of biological chemistry.

[11]  B. Matthews,et al.  Three-dimensional structure of human basic fibroblast growth factor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[12]  M. Capogrossi,et al.  Platelet-derived Growth Factor-BB and Basic Fibroblast Growth Factor Directly Interact in Vitro with High Affinity* , 2002, The Journal of Biological Chemistry.

[13]  T. Fan,et al.  Quantification of the repair process involved in the repair of a cell monolayer using an in vitro model of mechanical injury , 2004, Angiogenesis.

[14]  M. Rusnati,et al.  Basic fibroblast growth factor: Production, mitogenic response, and post‐receptor signal transduction in cultured normal and transformed fetal bovine aortic endothelial cells , 1989, Journal of cellular physiology.

[15]  D. Rifkin,et al.  Recent developments in the cell biology of basic fibroblast growth factor , 1989, The Journal of cell biology.

[16]  A Vacca,et al.  Basic fibroblast growth factor overexpression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[17]  C. Garlanda,et al.  The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. , 2000, Blood.

[18]  D. Rifkin,et al.  Alpha 2-macroglobulin is a binding protein for basic fibroblast growth factor. , 1989, The Journal of biological chemistry.

[19]  T. Eberlein,et al.  T lymphocytes that infiltrate tumors and atherosclerotic plaques produce heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor: a potential pathologic role. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[20]  C. Garlanda,et al.  Non-redundant role of the long pentraxin PTX3 in anti-fungal innate immune response , 2002, Nature.

[21]  G Olivetti,et al.  PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. , 2000, Circulation.

[22]  C. Gajdusek,et al.  Injury‐induced release of basic fibroblast growth factor from bovine aortic endothelium , 1989, Journal of cellular physiology.

[23]  A. Isacchi,et al.  A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Bikfalvi,et al.  Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization. , 1998, Blood.

[25]  M. Nugent,et al.  Fibroblast growth factor-2. , 2000, The international journal of biochemistry & cell biology.

[26]  L. Orci,et al.  Plasminogen activator inhibitor‐1 is induced in migrating endothelial cells , 1992, Journal of cellular physiology.

[27]  C. Garlanda,et al.  Production of the Long Pentraxin PTX3 in Advanced Atherosclerotic Plaques , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[28]  D. Gospodarowicz,et al.  The identification and partial characterization of the fibroblast growth factor receptor of baby hamster kidney cells. , 1985, The Journal of biological chemistry.

[29]  Francesco Tedesco,et al.  Multimer Formation and Ligand Recognition by the Long Pentraxin PTX3 , 1997, The Journal of Biological Chemistry.

[30]  M. Matsumoto,et al.  Hypoxia-mediated induction of acidic/basic fibroblast growth factor and platelet-derived growth factor in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Moscatelli,et al.  High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells , 1987, Journal of cellular physiology.

[32]  A. Mantovani,et al.  Endothelial cells overexpressing basic fibroblast growth factor (FGF-2) induce vascular tumors in immunodeficient mice , 2004, Angiogenesis.

[33]  L. Reis,et al.  TSG‐14 transgenic mice have improved survival to endotoxemia and to CLP‐induced sepsis , 2001, Journal of leukocyte biology.

[34]  C. Garlanda,et al.  Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration , 2001, Neuroscience.

[35]  M. Rusnati,et al.  Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans , 1996, International journal of clinical & laboratory research.

[36]  T. Blundell,et al.  Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. , 1996, Blood.

[37]  J. Folkman Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[38]  R. Abagyan,et al.  Long pentraxins: an emerging group of proteins with diverse functions. , 1996, Cytokine & growth factor reviews.

[39]  E. De Clercq,et al.  Inhibition of Fibroblast Growth Factor-2-induced Vascular Tumor Formation by the Acyclic Nucleoside Phosphonate Cidofovir 1 , 2001 .

[40]  T. Eberlein,et al.  T lymphocytes synthesize and export heparin-binding epidermal growth factor-like growth factor and basic fibroblast growth factor, mitogens for vascular cells and fibroblasts: differential production and release by CD4+ and CD8+ T cells. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[41]  A Vacca,et al.  New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. , 1997, Journal of vascular research.

[42]  D. Rifkin,et al.  Basic fibroblast growth factor, a protein devoid of secretory signal sequence, is released by cells via a pathway independent of the endoplasmic reticulum‐Golgi complex , 1992, Journal of cellular physiology.

[43]  R. Gallo,et al.  Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice. , 1997, Journal of immunology.

[44]  S. Tapscott,et al.  Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[45]  L. Morbidelli,et al.  Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. , 1993, The Journal of clinical investigation.

[46]  M. Byrne,et al.  Knockout of pentraxin 3, a downstream target of growth differentiation factor-9, causes female subfertility. , 2002, Molecular endocrinology.

[47]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[48]  P. Dell’Era,et al.  Nuclear localization of endogenous basic fibroblast growth factor in cultured endothelial cells. , 1991, Experimental cell research.

[49]  M. Berry,et al.  Transforming growth factor-beta 1 and basic fibroblast growth factor in the injured CNS. , 1993, Trends in pharmacological sciences.

[50]  A. Mantovani,et al.  Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipoarabinomannan , 1997, Infection and immunity.

[51]  H. Augustin,et al.  Basic fibroblast growth factor (bFGF) regulates the expression of the CC chemokine monocyte chemoattractant protein-1 (MCP-1) in autocrine-activated endothelial cells. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[52]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[53]  C. Barnes,et al.  Narp, a novel member of the pentraxin family, promotes neurite outgrowth and is dynamically regulated by neuronal activity , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[54]  M. Ziche,et al.  Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. , 1999, Molecular biology of the cell.

[55]  D. Becker,et al.  Antisense targeting of basic fibroblast growth factor and dibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth , 1997, Nature Medicine.

[56]  A. Wellstein,et al.  An FGF‐binding protein (FGF‐BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF‐2 release , 2001, International journal of cancer.

[57]  D. Moscatelli,et al.  The FGF family of growth factors and oncogenes. , 1992, Advances in cancer research.

[58]  A. Mantovani,et al.  Inducible expression of the long pentraxin PTX3 in the central nervous system , 2000, Journal of Neuroimmunology.

[59]  H. Granger,et al.  Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. , 1997, Circulation research.

[60]  A. Mantovani,et al.  Expression and production of the long pentraxin PTX3 in rheumatoid arthritis (RA) , 2000, Clinical and experimental immunology.

[61]  D. McDonald,et al.  Time course of endothelial cell proliferation and microvascular remodeling in chronic inflammation. , 2001, The American journal of pathology.

[62]  Y. Hsu,et al.  Human neuronal pentraxin II (NPTX2): conservation, genomic structure, and chromosomal localization. , 1995, Genomics.

[63]  E. Levine,et al.  Bovine endothelial cells transformed in vitro by benzo(a)pyrene , 1983, Journal of cellular physiology.

[64]  E. Rofstad,et al.  Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. , 2000, Cancer research.

[65]  V. Torri,et al.  Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients , 2001, Critical care medicine.